Register for Positive results announced for long-term study of Zeatin
AgingApril 8, 2004
2004 APR 8 - (NewsRx.com & NewsRx.net) -- Senetek PLC (SNTK) announced uniformly positive results for its multi-faceted study of the effects of its patented adenine derivative Zeatin on human skin cells.
The study, conducted at the University of Aarhus, Denmark, evaluated the effects of two concentrations of Zeatin on cultured human skin fibroplasts over their approximately 300-day lifespan in lab culture.
The new results were consistent with earlier studies of Zeatin and Senetek's lead anti-aging compound Kinetin, which suggested that at higher concentrations Zeatin was more effective than Kinetin in certain measures of bioactivity.
The new study shows that Zeatin does not interfere with the genetic control of cellular lifespan in early passage (young) or late passage (old) cells, that Zeatin promotes maintenance of small cell size (a key determinant of youthful skin) and structural and functional integrity, and that Zeatin prevents accumulation of macromolecular damage in the cell.
The study further found that Zeatin increases the activity of the antioxidant enzymes catalase and glutathione peroxidase, to counteract free radical-induced oxidative damage during cell aging, and that Zeatin-treated cells are more resistant to ethanol- and hydrogen peroxide-induced cell death, suggesting enhanced stress tolerance of the treated cells.
Based on these results, Senetek announced it will be undertaking a full program of pre-clinical trials at a noted life sciences laboratory overseas.
Dr. Brian F. C. Clark, co-discoverer with Dr. Suresh Rattan of the anti-aging and antioxidant effects of the cytokinin class to which Kinetin and Zeatin belong, commented, "Although Zeatin shares many aspects of bioactivity with its analogue Kinetin, as exemplified by their general effects in delaying aging characteristics in human cell cultures, Kinetin is found in the cell's DNA while Zeatin is found in RNA, and they have quite different chemistries which we plan to investigate in depth with modern technologies.
Among other things, the new study raises intriguing questions about the potential synergistic effects of these two compounds in a product regimen or in combination products."
Senetek is a life sciences-driven product development and licensing company focused on the high growth market for dermatological and skincare products primarily addressing photoaging and age-related skin conditions. This article was prepared by Women's Health Weekly editors from staff and other reports. Copyright 2004, Women's Health Weekly via NewsRx.com & NewsRx.net.
©Copyright 2004, Cardiovascular Week via NewsRx.com & NewsRx.net
